Showing studies matching your search4 results shown
Studies (4 shown)
NCT06563999PHASE2RECRUITING
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Sponsor · Sun Yat-sen UniversityCondition · Lung Cancer Stage III, MutationIntervention · Sunvozertinib, CrizotinibUpdated Apr 2026
NCT05009329PHASE1, PHASE2ACTIVE_NOT_RECRUITING
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Sponsor · Allist Pharmaceuticals, Inc.Condition · NSCLC, Solid TumorIntervention · JAB-21822, JAB-21822Updated Mar 2026
NCT06008288PHASE2RECRUITING
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Sponsor · Allist Pharmaceuticals, Inc.Condition · KRAS P.G12C, Pancreatic CancerIntervention · JAB-21822Updated Mar 2026
NCT07339839PHASE1, PHASE2NOT_YET_RECRUITING
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Sponsor · Cancer Institute and Hospital, Chinese Academy of Medical SciencesCondition · NSCLC Stage IV, KRAS G12CIntervention · Glecirasib, IvonescimabUpdated Jan 2026
Showing top 4 results. See all 4 results on CT.gov →